Últimas noticias sobre Merck & Co (NYSE:MRK) Bolsa

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Dividends

Trading Ideas

AMGN

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

Descubre las acciones del Dow Jones con los rendimientos por dividendos más altos para 2025. Conoce estrategias populares.

Acciones con mayores dividendos del Dow Jones: Las mejores opciones para 2025

Analyst Color

Equities

Long Ideas

News

Markets

GOOG

GOOGL

MSFT

TSLA

¿Qué acciones del Dow Jones prometen mejores rendimientos en 2025? Analizamos los datos y proyecciones más recientes.

Descubre las acciones del Dow Jones con más ganancias potenciales en 2025 según los analistas

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

Morgan Stanley analyst Terence Flynn maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Equal-Weight and lowers the price target from $123 to $113.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $113

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Large Cap

Regulations

Health Care

General

ABBV

TEVA

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

Looking into the current session, Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shares are trading at $99.85, after a 0.20% increase. Moreover, over the past month, the stock increased by 1.33%, but in the past year, fell by 15.94%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736946007_0.png" alt="Past Year Chart" />

<h3>How Does Merck &amp; Co P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Merck &amp; Co has a lower P/E than the aggregate P/E of 26.93 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736946007_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Merck & Co

Leerink Partners analyst Daina Graybosch maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Outperform and lowers the price target from $136 to $119.

Leerink Partners Maintains Outperform on Merck & Co, Lowers Price Target to $119

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

UBS analyst Colin Bristow maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and lowers the price target from $125 to $120.

UBS Maintains Buy on Merck & Co, Lowers Price Target to $120

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised the price target for Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from $375 to $400. Needham analyst Scott Berg maintained a Buy rating. Salesforce shares closed at $324.93 on Tuesday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities slashed Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) price target from $130 to $110. Truist Securities analyst Robyn Karnauskas downgraded the stock from Buy to Hold. Wendy&#8217;s shares closed at $101.02 on Tuesday. <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) from $17.5 to $26. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Intuitive Machines shares closed at $19.87 on Tuesday. <a href="https://www.benzinga.com/quote/LUNR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from $311 to $357. Piper Sandler analyst Clarke Jeffries upgraded the stock from Neutral to Overweight. Autodesk shares closed at $290.82 on Tuesday. See how other analysts view this stock.</li>
<li>B of A Securities boosted Ferguson Enterprises Inc. (NYSE FERG) price target from $185 to $225. B of A Securities analyst Arnaud Lehmann upgraded the stock from Underperform to Buy. Ferguson shares settled at $172.21 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) price target from $95 to $103. Jefferies analyst Matthew Taylor upgraded the stock from Hold to Buy. GE HealthCare shares closed at $83.37 on Tuesday. <a href="https://www.benzinga.com/quote/GEHC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $265 to $300. Deutsche Bank analyst Brad Zelnick upgraded the stock from Hold to Buy. Workday shares closed at $249.68 on Tuesday.  <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley boosted the price target for NetEase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) from $90 to $108. Morgan Stanley analyst Alex Poon upgraded the stock from Equal-Weight to Overweight. NetEase shares settled at $89.72 on Tuesday. <a href="https://www.benzinga.com/quote/NTES/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities raised Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) price target from $62 to $65. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. Bristol-Myers Squibb shares closed at $57.14 on Tuesday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) price target from $2,150 to $1,950. JP Morgan analyst Marcelo Santos maintained a Neutral rating. MercadoLibre shares closed at $1,771.22 on Tuesday. <a href="https://www.benzinga.com/quote/MELI/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

ADSK

GEHC

LUNR

MELI

NTES

WDAY

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Truist Securities analyst Robyn Karnauskas downgraded the rating for Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowered the price target from $130 to $110. Merck shares closed at $101.02 on Tuesday. <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Alex Scott downgraded American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) from Buy to Neutral and lowered the price target from $83 to $79. American Intl shares closed at $72.59 on Tuesday. <a href="https://www.benzinga.com/quote/AIG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Brad Zelnick downgraded the rating for Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Buy to Hold and lowered the price target from $207 to $190. Palo Alto shares closed at $175.51 on Tuesday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Vikram Bagri downgraded the rating for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Neutral to Sell and cut the price target from $12 to $9. SolarEdge Technologies shares closed at $17.59 on Tuesday. <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Brad Zelnick downgraded Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) from Buy to Hold and lowered the price target from $600 to $475. Adobe shares closed at $422.63 on Tuesday. <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADBE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08071359/image-45-1024x589.png" alt="" class="wp-image-723790" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08071359/image-45-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08071359/image-45-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08071359/image-45-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08071359/image-45.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Downgrades

ADBE

PANW

SEDG

This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Merck Announced That The National Medical Products Administration Of China Approved Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, And 18) Vaccine] For Use In Males 9-26 Years Of Age To Help Prevent Certain HPV-related Cancers And Diseases

Truist Securities analyst Robyn Karnauskas downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowers the price target from $130 to $110.

Truist Securities Downgrades Merck & Co to Hold, Lowers Price Target to $110

Jefferies upgraded Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>), noting that 2024 was a banner year for the PD-(L)1xVEGF class.
Summit Therapeutics&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China demonstrated a statistically significant improvement in progression-free survival compared to monotherapy Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41724651/summit-therapeutics-unique-investment-in-oncology-lead-drug-candidate-shows-promise" rel="noreferrer noopener">Keytruda (pembrolizumab)</a>.
The trial update sparked industry buzz and drove Summit Therapeutic&#8217; stock up around 150%, BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) up ~40%, and Instil Bio up ~500%.
Jefferies estimates the PD-(L)1xVEGF class could reach over $40 billion, similar to the PD-(L)1 class.
Analyst Kelly Shi expects the hype to continue in 2025 with two key upcoming catalysts: Ivonescimab HARMONi-2 overall survival data (expected in YE25/Early26) and first global Phase 3 data (expected in mid-25).
The analyst anticipates positive results from both and continued excitement to attract more deals in the space.
Jefferies analyst sees an encouraging upside for Instil Bio as its SYN2510 is the third US asset with a global trial planned in 2025.
In September, Instil and ImmuneOnco Biopharmaceuticals (Shanghai) announced the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer and in front-line <a href="https://www.benzinga.com/pressreleases/24/09/g40873356/instil-bio-and-immuneonco-announce-global-registrational-strategy-for-pd-l1xvegf-bispecific-antibo" target="_blank" rel="noreferrer noopener">triple-negative breast cancer</a>.
Jefferies upgraded Instil Bio from Hold to Buy with a price target of $52, over a 300% jump from a prior target of $11.
SYN2510 is a promising contender in its field, with significant potential driven by clinical data updates and business development interest in this drug class.
In 2024, three deals with a total upfront of $1.4 billion and a deal value of $6.4 billion were announced.
SYN2510 (PD-L1xVEGF-trap), BioNTech&#8217;s Biotheus <a href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" target="_blank" rel="noreferrer noopener">deal for BNT327</a> and Merck&#8217;s LM-299 deal mark the first big Pharma joining the fray, adding confidence in its <a href="https://www.benzinga.com/pressreleases/24/11/b41967094/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1vegf-bispecific-" target="_blank" rel="noreferrer noopener">mechanism of action</a>.
Price Action: TIL stock is up 22.4% at $24.90 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42854744/pacira-biosciences-secures-fda-approval-for-new-iovera-smarttip-to-manage-chronic-low-back-pain" target="_blank" rel="noreferrer noopener">Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain</a></li>
</ul>

Upgrades

Movers

BNTX

SMMT

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

High-rolling investors have positioned themselves bearish on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MRK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Merck &amp; Co. This is not a typical pattern.
The sentiment among these major traders is split, with 12% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $30,498, and 7 calls, totaling $404,215.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $115.0 for Merck &amp; Co over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck &amp; Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck &amp; Co's significant trades, within a strike price range of $50.0 to $115.0, over the past month.
<h3>Merck &amp; Co Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736276440_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$14.4</td>
<td>$13.95</td>
<td>$14.3</td>
<td>$95.00</td>
<td>$173.0K</td>
<td>219</td>
<td align="right">121</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$14.05</td>
<td>$13.1</td>
<td>$13.6</td>
<td>$95.00</td>
<td>$54.5K</td>
<td>420</td>
<td align="right">40</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$2.62</td>
<td>$2.87</td>
<td>$115.00</td>
<td>$43.0K</td>
<td>131</td>
<td align="right">177</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.12</td>
<td>$2.07</td>
<td>$2.08</td>
<td>$110.00</td>
<td>$41.6K</td>
<td>5.8K</td>
<td align="right">22</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.15</td>
<td>$8.95</td>
<td>$9.03</td>
<td>$95.00</td>
<td>$36.1K</td>
<td>500</td>
<td align="right">47</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Where Is Merck &amp; Co Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,413,468, the MRK's price is up by 1.57%, now at $101.29. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $113.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital downgraded its action to Market Perform with a price target of $105. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $121. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Unpacking the Latest Options Trading Trends in Merck & Co

On Monday, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) announced the acquisition of WuXi Vaccines&#8216; manufacturing site in Dundalk, Co Louth, marking a significant expansion of its operations in Ireland.
The $520.1 million (500 million euros) investment highlights Merck&#8217;s commitment to the region. It builds on a 3 billion euro investment in Ireland over the past three years.
The move aligns with Merck&#8217;s broader growth strategy, which includes plans to add approximately 1,000 jobs nationwide in the coming year.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
The Dundalk facility, spanning 15,520 square meters, is a three-story manufacturing hub.
It houses drug substance and product manufacturing units and quality control laboratories dedicated to producing vaccine products for global distribution. The site currently employs around 200 professionals and plans to hire an additional 150 workers.
The acquisition brings Merck&#8217;s total locations in Ireland to eight, covering Carlow, Cork, Dublin, Louth, Meath and Tipperary. Over 3,000 people are employed across the network.
Merck and WuXi Vaccines are now entering a formal handover process, expected to conclude in the first half of 2025. Once complete, the facility will bolster Merck&#8217;s ability to meet the growing global vaccine demand.
In 2024, Merck announced a 1 billion euro investment across its Carlow and Dunboyne facilities, further showcasing its commitment to scaling its Irish operations.
Price Action: MRK stock is up 0.24% at $99.96 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/42843417/nvidia-highlights-ai-chips-powering-pubg-robotics-chatgpt-moment-automotive-expansion-and-more-at-ces-event" target="_blank" rel="noreferrer noopener">Nvidia Highlights AI Chips Powering PUBG, Robotics &#8216;ChatGPT Moment,&#8217; Automotive Expansion And More At CES Event</a></li>
</ul>

Contracts

Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million

WIIM

Merck & Compnay and OPKO Health shares are trading higher after the companies announced a license and collaboration agreement to develop an Epstein-Barr virus vaccine.

OPKO Health's ModeX Therapeutics Begins Phase I Trial For Epstein-Barr Virus Vaccine In Collaboration With Merck; First Participant Dosed, Milestone Payment Triggered By Merck

JPMorgan has reset the valuation for Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) and Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>).
Analyst Hardik Parikh cites several reasons for recovery, including pathways for strategic partnership with pharma, some clinical trial data points and additional clarity on the incoming administration&#8217;s policies on GLP-1 access.
The analyst writes that <a target="_blank" href="https://www.benzinga.com/quote/VKTX" rel="noreferrer noopener">Viking Therapeutics</a> and <a target="_blank" href="https://www.benzinga.com/quote/GPCR" rel="noreferrer noopener">Structure Therapeutics</a> are attractive pure-play options for investing in the T2D/obesity market opportunity overall.
The note continues, saying that Viking Therapeutics and Structure Therapeutics remain attractive partners for pharmaceutical companies looking to enter the T2D/obesity market relatively quickly.
It expects a reasonable case to make that many pharmaceutical companies, in addition to Merck &amp; Co. Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), could be active in the space. Hence, Viking Therapeutics and Structure Therapeutics still have abundant pathways <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42560386/whats-going-on-with-viking-therapeutics-stock-on-wednesday" rel="noreferrer noopener">to strategic partnerships</a>.
Viking Therapeutics and Structure Therapeutics can help address growth gaps for pharma over time, analyst Parikh says, and sees an apparent disconnect on valuation abates over time.
The analyst sees the competitive bar for VK2735 primarily unchanged, at least in the near term, after Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) phase 3 Redefine-1 data showed weight loss from cagriSema that is on par with Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.
The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">injectables in development</a>.
Viking Therapeutics highlighted new clinical data from its VK2735 obesity program in two poster presentations&nbsp;at ObesityWeek&nbsp;2024.
Cohorts receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">ranging up to 8.2%</a>.
JPMorgan suggests that VK2735&#8217;s weight-loss effectiveness in its upcoming Phase 3 trial (starting in early 2025) could slightly surpass Zepbound&#8217;s ~22% reduction at 72 weeks and remain competitive with CagriSema.
However, the firm believes Eli Lilly&#8217;s retatrutide may set the highest standard for efficacy, potentially achieving weight loss in the high 20% range, based on Phase 3 data expected in 2026. While this creates a challenging benchmark for VK2735, its tolerability could offer an edge over retatrutide, which is expected to have slightly more side effects than Zepbound.
Last month, Structure Therapeutics selected ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity and related diseases. The compound is expected to be in Phase 1 clinical development by the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42539839/structure-therapeutics-announces-selection-of-lead-oral-small-molecule-amylin-receptor-agonist-acc" rel="noreferrer noopener">end of 2025</a>.
In November, Structure Therapeutics dosed the first patient in Phase 2b ACCESS trial of GSBR-1290 obese or overweight patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41953633/structure-therapeutics-announces-first-patients-dosed-in-phase-2b-access-clinical-study-evaluating" rel="noreferrer noopener">weight-related comorbidity</a>.
VKTX, GCPR Price Actions: Viking Therapeutics stock is down 0.56% at $42.65, and Structure Therapeutics stock is down 0.25% at $27.51 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/01/42819611/cvs-health-aetna-files-lawsuit-against-drugmakers-for-alleged-inflated-generic-drug-prices" target="_blank" rel="noreferrer noopener">CVS Health&#8217;s Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

GPCR

VKTX

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity.
The <a target="_blank" href="https://www.gov.uk/government/news/sotatercept-approved-to-treat-adult-patients-with-pulmonary-arterial-hypertension-pah" rel="noreferrer noopener">recommended</a> dosing schedule is one injection every three weeks via self-administration.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
In March 2024, the FDA approved&nbsp;Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with PAH to increase exercise capacity, improve WHO functional class, and reduce the risk of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">clinical worsening events</a>.&nbsp;
A main study was conducted involving 323 patients with PAH. The study showed that sotatercept was more effective than placebo at improving the ability of adults with PAH to exercise. The main measure of effectiveness was the difference in the distance patients could walk in 6 minutes before and after treatment.
After 24 weeks of treatment, sotatercept given in addition to other PAH medicines, improved the distance patients could walk in 6 minutes by around 34 meters, compared with 1 meter in patients who received a placebo instead. The median (average) treatment difference between the sotatercept and placebo groups was 40.8 meters.
In November, Merck&nbsp;revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42169558/why-is-merck-stock-trading-higher-on-monday" rel="noreferrer noopener">high risk of mortality</a>.
ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours).
Price Action: MRK stock is up 0.56% at $100.04 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42766874/equinor-powers-up-empire-wind-1-project-with-financing-package-details" target="_blank" rel="noreferrer noopener">Equinor Powers Up Empire Wind 1 Project With Financing Package: Details</a></li>
</ul>
Image via Merck

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

Investors have many strategies when looking at stocks and options, including sector rotation, earnings strength and upcoming catalysts. Value investors often look for strong earnings strength <a href="https://www.benzinga.com/topic/dividend-stocks">from dividend stocks.</a>
The Dow Jones Industrial Average includes many dividend-paying stocks, including many blue-chip companies that have consistently raised their dividends.
Here&#8217;s a look at the top-yielding Dow Jones stocks heading into 2025.
What Happened: The<a href="https://www.benzinga.com/topic/dow-jones-industrial-average"> Dow Jones Industrial Average</a> hit a record high of 45,000 in December as one of many stock indexes to post gains after the 2025 presidential election.
As of Dec. 27, 18 of the Dow Jones Industrial Average stocks have gained year-to-date, while 12 components are trading lower compared to the start of 2024.
While investors can bet on the entire Dow Jones Industrial Average through ETFs like the Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), investors can also pick individual stocks from the 30 components of the index. Through Dec. 27, the ETF is up 13.4% year-to-date.
One popular strategy is to look at the &#8220;Dogs of the Dow,&#8221; which often coincides with the beaten-down stocks of the index that also offer high dividend payouts.
Here are the highest-yielding Dow Jones Industrial Average stocks to start 2025, with the dividend yield and stock performance in 2024 listed below.
<ol>
<li>Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.79% yield, +5.9% in 2024</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.53% yield, -3.5% in 2024</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.62% yield, -8.8% in 2024</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.42% yield, -7.5% in 2024</li>
<li>Merck &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 3.25% yield, -8.5% in 2024</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 3.11% yield, +6.0% in 2025</li>
<li>International Business Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): 3% yield, +36.2% in 2024</li>
<li>Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): 2.68% yield, +18.0% in 2024</li>
<li>McDonald's Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.41% yield, -1.0% in 2024</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.37% yield, +15.7% in 2024</li>
</ol>
Seven of the top 10 highest-yielding stocks heading into 2025 also appeared on the top 10 list to start 2024 with Merck, McDonald's and Procter &amp; Gamble the newcomers to the Dogs of the Dow list for the new year.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Component Changes Impact Yields: It's worth noting that dividend investors will have to look elsewhere to chase some of the higher-yielding stocks they have become accustomed to.
Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), which yields 10.40% and Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), which yields 6.99% have been replaced and removed from the index.
New 2024 Dow Jones Industrial Average components don't come with high dividend yields. Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) has a dividend yield of 0.80%, NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has a dividend yield of 0.03% and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) does not pay a dividend.
This means that the yield on ETFs that track the Dow Jones Industrial Average will be lower, with the goal of potentially stronger returns by replacing the underperforming stocks with stocks that have performed better over the past five years.
The latest 30 Dow Jones Industrial Average components see 28 stocks paying out dividends with Amazon and Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) the exceptions.
The average dividend yield of the Dow Jones Industrial Average is around 2%.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123024" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential.
Dow&#8217;s Performance In 2024
The Dow Jones Industrial Average index hit a record eight 1,000-point milestones this year. It started the year around the 37,000 level and breached the 45,000 level at the beginning of December. It took only seven trading days for the index to go from 44,000 to 45,000, the second fastest 1,000-point milestone ever.
Following that the index also saw one of its longest 10-day losing streak, the first ever since 1974. These 10 days of underperformance stems from a confluence of factors. 
The Dow doesn&#8217;t include all &#8220;Magnificent 7&#8221; stocks like Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). The recent inclusion of Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the Dow has also pulled the index down because of the stock&#8217;s underperformance.
Dow&#8217;s constituent UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has experienced a substantial decline this month following the tragedy with its CEO&#8217;s shooting. Moreover, in essence, the Dow&#8217;s historical advantage of its price-weighted indexing has become a significant disadvantage in today&#8217;s market. This is because, unlike market capitalization-weighted indices, higher-priced stocks have more weight in the calculation of a price-weighted index.
<h4 class="wp-block-heading">Dow Jones Stocks With The Best And Worst Return Potential</h4>
Analysts still expect that a group of stocks led by Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), UnitedHealth and Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) within the Dow will rise even more, according to estimates compiled by <a href="https://www.benzinga.com">Benzinga</a>. Others on the list are the Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
To be sure, analysts keep updating their forecasts based on company performance and may change their estimates as the new earnings season begins.
Selection Criteria:
<ul>
<li>The thirty blue-chip stocks in Down Jones.</li>
</ul>
<ul>
<li>The highest and lowest return potential is based on the average 12-month target prices from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.</li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Companies</td>
<td>M-Cap</td>
<td>Highest PT ($/Share)</td>
<td>Lowest PT ($/Share)</td>
<td>Consensus PT ($/Share)</td>
<td>Upside/Downside Potential</td>
</tr>
<tr>
<td>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</td>
<td>176.73B</td>
<td>515</td>
<td>174</td>
<td>331.35</td>
<td>31.68%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>460.26B</td>
<td>675</td>
<td>460</td>
<td>608.16</td>
<td>28.95%</td>
</tr>
<tr>
<td>Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)</td>
<td>86.71B</td>
<td>450</td>
<td>249</td>
<td>371.19</td>
<td>24.08%</td>
</tr>
<tr>
<td>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2,365.04B</td>
<td>290</td>
<td>197</td>
<td>247.05</td>
<td>23.82%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>347.83B</td>
<td>215</td>
<td>40</td>
<td>168</td>
<td>22.41%</td>
</tr>
<tr>
<td>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>)</td>
<td>256.71B</td>
<td>212</td>
<td>160</td>
<td>179.36</td>
<td>21.42%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc (NYSE: MRK</td>
<td>248.03B</td>
<td>155</td>
<td>104</td>
<td>126.24</td>
<td>20.76%</td>
</tr>
<tr>
<td>Salesforce Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>)</td>
<td>328.87B</td>
<td>450</td>
<td>236</td>
<td>378.52</td>
<td>20.60%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>3,246.07B</td>
<td>600</td>
<td>465</td>
<td>508</td>
<td>18.21%</td>
</tr>
<tr>
<td>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>622.63B</td>
<td>375</td>
<td>252</td>
<td>318.42</td>
<td>17.69%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Benzinga.com (Data as of Dec. 22, 2024)</figcaption></figure>
See Also: <a href="https://www.benzinga.com/24/12/42430296/carson-researchs-50-year-study-suggests-that-the-26-months-old-bull-market-is-far-from-over">Is The 26-Month Bull Market Over? Here Is What Carson Research&#8217;s 50-Year Old Study Tells Us</a>
<h3 class="wp-block-heading">Caterpillar Inc</h3>
<ul>
<li>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has the highest return potential of 31.68% among the Dow Jones constituents.</li>
</ul>
<ul>
<li>The 28 analysts tracking the company have a consensus price target of $331.35 per share, according to <a href="https://www.benzinga.com/quote/CAT/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Truist Securities&#8217; Jamie Cook raised the price target from $454 to $471 per share on Dec. 19, 2024 as he expects significant investments in infrastructure, likely driven by government initiatives and private sector projects to fuel demand for Caterpillar&#8217;s equipment.</li>
</ul>
<ul>
<li>Citigroup analyst Kyle Menges maintained a &#8216;buy&#8217; rating on the company and raised the price target from $435 to $460 apiece on Dec. 9, 2024.</li>
</ul>
<ul>
<li>On Dec. 9, JPMorgan analyst Tami Zakaria also reaffirmed her bullish stance on Caterpillar, maintaining a &#8216;buy&#8217; rating on the stock. Concurrently, she raised the firm&#8217;s price target for Caterpillar from $500 to $515 per share.</li>
</ul>
<h3 class="wp-block-heading">UnitedHealth Group</h3>
<ul>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has the second highest return potential of 28.95% among the Dow Jones constituents.</li>
</ul>
<ul>
<li>The 26 analysts tracking the company have a consensus price target of $331.35 per share, according to <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>Oppenheimer raised its price target to $640 from $610 apiece on Dec.6, 2024. The primary reason for the price target increase is that the Oppenheimer analyst is updating their financial model. This update appears to be based solely on the publicly available information disclosed by UnitedHealth in their 8-K filing.</li>
</ul>
<ul>
<li>Stephens &amp; Co raised its target price to $675 from $605 per share on Dec. 5, 2024, after conducting a detailed review of the 2025 guidance metrics that UnitedHealth had shared before the fatal shooting of CEO Brian Thompson that led to the cancellation of their investor conference.</li>
</ul>
<ul>
<li>Deutsche Bank also increased its target from $595 to $625 apiece as it believes investor positioning into the event is mostly neutral to positive, with almost no one expecting a negative revision versus the third quarter outlook.</li>
</ul>
<h3 class="wp-block-heading">Sherwin-Williams Company</h3>
<ul>
<li>Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) has a return potential of 24.08% going into 2025.</li>
</ul>
<ul>
<li>A consensus price target of $371.19 per share was maintained by 25 analysts that track the company, as per <a href="https://www.benzinga.com/quote/SHW/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Greg Melich from Evercore ISI raised the price target of the Ohio-based paints, coatings and related products manufacturer to $420 from $400 per share on Nov. 7, 2024.</li>
</ul>
<ul>
<li>RBC Capital&#8217;s Arun Viswanathan lowered his target on the company from $455 to $446 per share on Oct. 24, 2024. While acknowledging that third-quarter results might not have met investor expectations, Viswanathan emphasized the company&#8217;s potential for market share gains and the positive impact of its upcoming price increase scheduled for January 2025.</li>
</ul>
<ul>
<li>Citigroup adjusted its price target from $430 to $420 apiece on Oct. 24 as it anticipates choppy demand in the first half of 2025, which could hinder the rapid pass-through of interest rate cuts.</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">Trump&#8217;s Deregulation Efforts To Benefit Energy, Oil And Gas Sectors, While AI Frenzy Will Boost FAANG Stocks And Nvidia, Says Fintech Insider</a>
<h3 class="wp-block-heading">Amazon.com Inc</h3>
<ul>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has a return potential of 23.82% going into 2025.</li>
</ul>
<ul>
<li>A consensus price target of $247.05 per share was maintained by 39 analysts that track the company, as per <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Tigress Financial&#8217;s Ivan Feinseth umped is price target from $245 to $290 apiece on Dec.20, 2024 as it believes Amazon is well-positioned for continued success, driven by robust retail trends, effective utilization of generative AI and its fulfillment network, and the strategic integration of AI across its entire business.</li>
</ul>
<ul>
<li>The expectations of strong long-term growth driven by operational efficiency and sustained momentum across its business segments led Bernstein to raise its target price from $235 to $265 per share on Dec. 18, 2024.</li>
</ul>
<ul>
<li>According to JPMorgan analyst Douglas Anmuth, Amazon is a best idea for 2025, and confidence in AWS growth in the months to come is a major reason for that. He raised its target price from $250 to $280 apiece on Dec. 18, 2024.</li>
</ul>
<h3 class="wp-block-heading">Johnson &amp; Johnson</h3>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has the fifth highest return potential in Dow of 22.41% going into 2025.</li>
</ul>
<ul>
<li>The 21 analysts tracking the company have a consensus price target of $168 apiece, according to <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">Benzinga</a>. </li>
</ul>
<ul>
<li>Citigroup&#8217;s Joanne Wuensch lowered Johnson &amp; Johnson&#8217;s price target from $185 to $175 per share while maintaining a &#8216;buy&#8217; rating on Dec. 11, 2024.</li>
</ul>
<ul>
<li>BofA Securities reinstated coverage of Johnson &amp; Johnson with a &#8216;neutral&#8217; rating and a $166 price target on Dec. 10, 2024. BofA notes that J&amp;J&#8217;s current valuation premium to peers may limit upside potential. However, the analyst acknowledges a &#8220;fairly interesting&#8221; pipeline and anticipates that resolving the talc litigation in 2025 would be beneficial. This analysis was part of BofA&#8217;s broader coverage initiation of 11 large-cap U.S. pharmaceutical and biotechnology companies.</li>
</ul>
<ul>
<li>Wolfe Research analyst Alexandria Hammond commenced coverage of Johnson &amp; Johnson with an &#8216;outperform&#8217; recommendation and established a price target of $190 per share on Nov. 15, 2024</li>
</ul>
<h3 class="wp-block-heading">Chevron Corporation</h3>
<ul>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) has a return potential of 21.42% going into 2025.</li>
</ul>
<ul>
<li>The 24 analysts tracking the company have a consensus price target of $179.36 apiece, according to <a href="https://www.benzinga.com/quote/CVX/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>Piper Sandler analyst Ryan Todd reduced his price target on the company from $184 to $173 per share on Dec. 19, 2024, while maintaining a &#8216;buy&#8217; rating. Piper Sandler suggests the valuation gap between Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron implies a probability of over 65% of the Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) deal failing out. This scenario presents a potential 15%-25% upside, while a successful deal offers a 5%-10% downside ahead of the upcoming arbitration.</li>
</ul>
<ul>
<li>Despite this deal uncertainty, Piper expects Chevron to deliver strong portfolio performance in 2025, driven by project starts and controlled capital expenditures. This is projected to result in a significant free cash flow increase of $6-$7 billion.</li>
</ul>
<ul>
<li>Wells Fargo analyst Roger Read raised his target price from $171 to $188 apiece on Dec. 9, 2024</li>
</ul>
<ul>
<li>Truist Securities raised its price target on Chevron to $160 from $155 while maintaining a &#8216;hold&#8217; rating, on Dec. 6, 2024. The analyst highlights Chevron&#8217;s significant inventory, including ample royalties, and expects improved capital efficiency to drive a cash flow inflection in the coming year.</li>
</ul>
<h3 class="wp-block-heading">Merck &amp; Co Inc</h3>
<ul>
<li>Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) has the seventh highest return potential in Dow of 20.76% going into 2025.</li>
</ul>
<ul>
<li>The 27 analysts tracking the company have a consensus price target of $126.24 apiece, according to <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">Benzinga</a>.</li>
</ul>
<ul>
<li>BMO Capital Markets downgraded Merck to &#8216;market perform&#8217; from &#8216;outperform&#8217; lowering the price target from $136 to $105 apiece, on Dec. 20, 2024. The downgrade reflects concerns about the company&#8217;s Gardasil franchise in China and the potential revenue gap as Keytruda faces increased competition from biosimilars and generic drugs.</li>
</ul>
<ul>
<li>Tim Anderson from BofA Securities maintains his bullish stance on Merck with a &#8216;buy&#8217; rating, while adjusting the price target downward to $121 from $127 per share, on Dec. 10, 2024.</li>
</ul>
<ul>
<li>Truist analyst Robyn Karnauskas reaffirms a &#8216;buy&#8217; rating for Merck on Nov. 7, 2024, but lowers the price target to $130 from $132 apiece.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42642834/market-breadth-turns-positive-after-a-rare-14-day-negative-streak-history-suggests-gains-ahead">Market Breadth Rebounds As Risk Appetite Makes A Comeback: This Analyst Predicts Gains Ahead After S&amp;P 500&#8217;s Record Negative Streak</a></li>
</ul>
Photo courtesy: Shutterstock

Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025

Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership

Top 4 Immunology Stocks Poised For Growth In 2025

High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent

IYH: Healthcare Dashboard For January

Merck: 3x Pipeline And Undervaluation Make It A Buy

Viking Therapeutics: The Turning Point Is Not Here Yet

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Healthcare And Biotech Stocks Lag The Market Again

Analysts fell to the sidelines weighing in on Inspire Medical Systems (INSP – Research Report) and Merck & Company (MRK – Research Report) with neu...

Analysts Are Neutral on These Healthcare Stocks: Inspire Medical Systems (INSP), Merck & Company (MRK)

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the share...

Merck price target lowered to $113 from $123 at Morgan Stanley

Takeda-backed Ascentage Pharma sets terms for $170M IPO

ALVO

ALVOW

ARGX

ASPHF

AZNCF

BIIB

BMYMP

CGEM

CHRS

CNMD

COLL

CPRX

FBCG

GLAXF

HRMY

IFRX

INCY

INSP

INTU

ISRG

IVBIY

IVBXF

LANC

LECO

LRCX

MKTX

MRNA

NONOF

QCOM

RHHBF

RHHBY

RHHVF

ROIV

RSPH

SDZNY

SDZXF

SNYNF

TEVJF

TKPHF

VTRS

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Merck's GARDASIL® Receives Expanded Approval for Males in China

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

Comments

Merck & Co

Noticias

Últimas noticias sobre Merck & Co (NYSE:MRK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL